{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:17:07Z","timestamp":1793758627485,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41416-018-0274-8","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T08:18:39Z","timestamp":1539332319000},"page":"1401-1409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes"],"prefix":"10.1038","volume":"119","author":[{"given":"Darren R.","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitra","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Grinsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony W.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane D.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry S.","family":"Lanchbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Timms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Womack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Carl","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier, Y., O\u2019Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 362ps17 (2016).","journal-title":"Sci. Transl. Med."},{"key":"274_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68\u201378 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"274_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"274_CR4","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/1538-7445.AM2013-4420","volume":"73","author":"MJ O\u2019Connor","year":"2013","unstructured":"O\u2019Connor, M. J. et al. Generating preclinical models to assess bone marrow toxicity induced by the PARP inhibitor olaparib in combination with chemotherapy. Cancer Res. 73, 4420 (2013).","journal-title":"Cancer Res."},{"key":"274_CR5","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109\u20138115 (2006).","journal-title":"Cancer Res."},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852\u2013861 (2014).","journal-title":"Lancet Oncol."},{"key":"274_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764\u2013775 (2014).","journal-title":"Clin. Cancer Res."},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","volume":"8","author":"CJ Lord","year":"2008","unstructured":"Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363\u2013369 (2008).","journal-title":"Curr. Opin. Pharmacol."},{"key":"274_CR10","doi-asserted-by":"crossref","unstructured":"Dougherty, B. et al. Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition. Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA, 18\u201322 April, abst 611 (2015).","DOI":"10.1158\/1538-7445.AM2015-611"},{"key":"274_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).","journal-title":"Lancet Oncol."},{"key":"274_CR12","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med"},{"key":"274_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"274_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med 366, 1382\u20131392 (2012).","journal-title":"N. Engl. J. Med"},{"key":"274_CR15","unstructured":"Myriad Genetic Laboratories. BRACAnalysis\u00ae technical specifications. https:\/\/www.myriad.com\/lib\/technical-specifications\/BRACAnalysis-Technical-Specifications.pdf (accessed 24 Dec. 2013) (2012)"},{"key":"274_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023\u20131031 (2013).","journal-title":"Nat. Biotechnol."},{"key":"274_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms, K. M. et al. Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16, 475 (2014).","journal-title":"Breast Cancer Res"},{"key":"274_CR19","unstructured":"Myriad. Tumor BRACAnalysis CDxTM. http:\/\/myriadgenetics.eu\/products\/tumor-bracanalysis-cdx-2\/?lang=gb (1 January 2017)."},{"key":"274_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","volume":"16","author":"EA Stronach","year":"2018","unstructured":"Stronach, E. A. et al. Biomarker assessment of HR deficiency, tumor BRCA1\/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Mol. Cancer Res. 16, 1103\u20131111 (2018).","journal-title":"Mol. Cancer Res."},{"key":"274_CR20","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","volume":"23","author":"S Lheureux","year":"2017","unstructured":"Lheureux, S. et al. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization. Clin. Cancer Res. 23, 4086\u20134094 (2017).","journal-title":"Clin. Cancer Res"},{"key":"274_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev. Med. 66, 455\u2013470 (2015).","journal-title":"Annu Rev. Med."},{"key":"274_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fonc.2014.00005","volume":"4","author":"SH George","year":"2014","unstructured":"George, S. H. & Shaw, P. BRCA and early events in the development of serous ovarian cancer. Front. Oncol. 4, 5 (2014).","journal-title":"Front. Oncol."},{"key":"274_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235\u2013244 (2010).","journal-title":"Lancet"},{"key":"274_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245\u2013251 (2010).","journal-title":"Lancet"},{"key":"274_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852\u2013861 (2011).","journal-title":"Lancet Oncol."},{"key":"274_CR26","first-page":"1469","volume":"25","author":"S Pignata","year":"2015","unstructured":"Pignata, S. et al. ORZORA: open-label phase IV trial of olaparib in patients with BRCA-mutated ovarian cancer. Int. J. Gynaecol. Cancer 25, 1469\u20131470 (2015).","journal-title":"Int. J. Gynaecol. Cancer"},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.955","volume":"43","author":"T Rafnar","year":"2011","unstructured":"Rafnar, T. et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat. Genet. 43, 1104\u20131107 (2011).","journal-title":"Nat. Genet."},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"djv214","DOI":"10.1093\/jnci\/djv214","volume":"107","author":"SJ Ramus","year":"2015","unstructured":"Ramus, S. J. et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J. Natl. Cancer Inst. 107, djv214 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"274_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jmedgenet-2015-103529","volume":"53","author":"DF Easton","year":"2016","unstructured":"Easton, D. F. et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J. Med. Genet. 53, 298\u2013309 (2016).","journal-title":"J. Med. Genet."},{"key":"274_CR30","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","volume":"289","author":"PM Joshi","year":"2014","unstructured":"Joshi, P. M., Sutor, S. L., Huntoon, C. J. & Karnitz, L. M. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289, 9247\u20139253 (2014).","journal-title":"J. Biol. Chem."},{"key":"274_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"274_CR32","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25, 2158\u20132172 (2011).","journal-title":"Genes Dev."},{"key":"274_CR33","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1158\/0008-5472.CAN-15-2128","volume":"76","author":"T Popova","year":"2016","unstructured":"Popova, T. et al. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 76, 1882\u20131891 (2016).","journal-title":"Cancer Res."},{"key":"274_CR34","doi-asserted-by":"publisher","first-page":"abstr 5561","DOI":"10.1200\/JCO.2018.36.15_suppl.5561","volume":"36","author":"JI Weberpals","year":"2018","unstructured":"Weberpals, J. I. et al. Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients. J. Clin. Oncol. 36, abstr 5561 (2018).","journal-title":"J. Clin. Oncol."},{"key":"274_CR35","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode, E. L. et al. Dose-response association of CD8+tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 3, e173290 (2017).","journal-title":"JAMA Oncol."},{"key":"274_CR36","unstructured":"AstraZeneca. Global Policy: Bioethics. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/Bioethics_policy.pdf (2016)"},{"issue":"7","key":"274_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M. Esteller","year":"2000","unstructured":"Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564\u2013569 (2000).","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"274_CR38","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","volume":"50","author":"I. Ruscito","year":"2014","unstructured":"Ruscito, I. et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients \u2013 a study of the tumour bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur. J. Cancer 50, 2090\u20132098 (2104).","journal-title":"European Journal of Cancer"},{"issue":"6","key":"274_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/bjc.2013.70","volume":"108","author":"J L Lesnock","year":"2013","unstructured":"Lesnock, J. L. et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br. J. Cancer 108, 1231\u20131237 (2013).","journal-title":"British Journal of Cancer"},{"issue":"1","key":"274_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/CBM-150550","volume":"16","author":"Hiroyuki Nomura","year":"2016","unstructured":"Nomura, H. et al. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer. Cancer Biomark. 16, 145\u2013152 (2016).","journal-title":"Cancer Biomarkers"},{"issue":"3","key":"274_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00428-012-1368-y","volume":"462","author":"Roy Milner","year":"2013","unstructured":"Milner, R. et al. Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Virchows Arch. 462, 269\u2013279 (2013).","journal-title":"Virchows Archiv"},{"issue":"10","key":"274_CR42","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776\u20131782 (2012).","journal-title":"British Journal of Cancer"},{"key":"274_CR43","unstructured":"Watkins, J. A. et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014)."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0274-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:24Z","timestamp":1684616604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0274-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review boards or independent ethics committees of all investigational sites approved the protocol and all patients provided written, informed consent. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice and the AstraZeneca policy on bioethics.<sup>36<\/sup>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"D.R.H., B.A.D., Z.L., A.F., L.G., S.S., M.J.O.C., T.W.H., M.O., H.J. and J.C.B. are AstraZeneca employees and stockholders; J.D.R. and C.W. were AstraZeneca employees and stockholders at the time the study was conducted. J.S.L., K.M.T. and A.G. are Myriad Genetics Inc. employees and stockholders; C.G. has acted in an advisory role for AstraZeneca, Clovis, Roche and Nucana, received honoraria from AstraZeneca and Roche, and received research funding from AstraZeneca, Novartis and Aprea; J.L. has participated in an advisory board for AstraZeneca; B.G. declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was funded by AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}